Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway

Fig. 1

MLH1 protein and mRNA levels in cells subjected to different treatments. a MLH1 protein and mRNA expression levels in Ishikawa and RL95–2 cells were measured by Western blotting and qRT-PCR (**, P < 0.01). b Comparison of MLH1 protein and mRNA knockdown using siMLH1–528, siMLH1–1832 and siMLH1–2431 by Western blotting and qRT-PCR. si-MLH1-NC and untreated RL95–2 cells were used as controls. siMLH1–1832 dramatically downregulated MLH1 expression in RL95–2 cells compared with the siMLH1–528, siMLH1–2431 and siMLH1-NC groups (**, P < 0.01). c Western blotting and qRT-PCR showed upregulated MLH1 expression by ADV-MLH1 in Ishikawa cells (**, P < 0.01). β-actin was used as a loading control, and mRNA levels were normalized to U6. Data are presented as the mean ± SEM of three experiments

Back to article page
\